NCT06496243View on ClinicalTrials.gov

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

PHASE2RecruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

February 28, 2026

Conditions
Dyslipidemias
Interventions
DRUG

obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks

10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks

Trial Locations (1)

19104

RECRUITING

UPenn, Philadelphia

Sponsors
All Listed Sponsors
lead

NewAmsterdam Pharma

INDUSTRY